The Trump administration is asking Americans for input on whether marijuana should be reclassified under international drug control treaties to which the U.S. is a party.
Currently, under both U.S. law and global agreements, marijuana sits in the most restrictive category of Schedule I. Domestically, that means it is not available for formal prescriptions and research on its effects is heavily restricted. Globally, it means that nations signed onto drug treaties are not supposed to legalize cannabis.
But now, the United Nations World Health Organization is set to launch a review of the current international classification of marijuana, THC, cannabidiol and other related compounds and preparations, and it wants input from member nations. In turn, the U.S. Food and Drug Administration is asking “interested persons” to submit comments that can inform the country’s position on the issue before it weighs in with the UN.
Specifically, FDA is inviting input on the “abuse potential, actual abuse, medical usefulness, trafficking and impact of scheduling changes on availability for medical use of” cannabis and its compounds, the agency wrote in a Federal Register notice scheduled to be published on Monday.
WHO’s Expert Committee on Drug Dependence will meet in June to discuss marijuana’s classification and will then make pre-review recommendations to the UN secretary-general about conducting a more in-depth analysis. Following that process, depending on the findings, cannabis could be rescheduled internationally, which would provide momentum to efforts to change marijuana’s status under the laws of the U.S. and other countries.
Last year the body pre-reviewed CBD, a non-psychoactive cannabis compound found to be have medical benefits, and recommended that it be subject to further analysis. The substance, which is not currently listed under international schedules but is considered Schedule I in the U.S., “has been demonstrated as an effective treatment of epilepsy in several clinical trials” and “is generally well tolerated with a good safety profile,” the WHO pre-review found.
“There is no evidence of…any public health related problems associated with the use of pure CBD,” the committee wrote.
Marijuana itself has never been subject to formal review since first being placed in Schedule I of the international agreement enacted in 1961, FDA notes in the new Federal Register notice.
Public comments are due to the FDA by April 23.
Last month, UN Secretary-General António Guterres used a speech before the body’s narcotics commission to tout the drug decriminalization law his home country of Portugal enacted when he was prime minister.
But also last month, the UN’s drug enforcement body issued a report warning countries not to legalize marijuana.
Photo courtesy of Chris Wallis // Side Pocket Images.
Hemp Legalization Is Officially Headed to President Trump’s Desk For Signature
The 2018 Farm Bill, which would legalize industrial hemp, is officially headed to President Donald Trump’s desk. The House passed the legislation on Wednesday, one day after the Senate approved it.
It’s been decades since the ban on hemp was imposed—a byproduct of the federal government’s war on marijuana and other drugs. The ban, it seems, will be lifted in a matter of days.
The House passed the bill, 369-47.
The votes come after months of debate over other aspects of the wide-ranging agriculture bill. But the hemp legalization provision, shepherded by Senate Majority Leader Mitch McConnell (R-KY), has received bipartisan support at every step of the legislative process.
Hemp legalization made it through a conference committee where the Senate and House Agriculture Committees reconciled their respective versions of the bill. McConnell marked the occasion this week by signing the conference report with a hemp pen, which he said on Wednesday that the president was free to use to sign the bill into law.
The hemp provision would allow U.S. farmers to grow, process and sell the crop. The Justice Department would no longer have jurisdiction over hemp under the legislation; rather, the U.S. Department of Agriculture would lightly regulate it.
One element of the hemp language created tension between lawmakers and advocates. The original Senate-passed bill prohibited people with felony drug convictions from participating in the hemp industry, but a compromise was reached last week that limited that ban in the final version to 10 years after the last offense.
House Democrats in the Agriculture Committee listed hemp legalization as one of several reasons they were calling for a “yes” vote on the legislation.
The farm bill conference report legalizes industrial hemp. pic.twitter.com/2u5xxtKwaS
— House Agriculture Committee Democrats (@HouseAgDems) December 12, 2018
According to VoteHemp, if the president signs the bill before the year’s end, it will take effect on January 1, 2019.
Marijuana Industry Border Issues Would Be Solved Under New Congressional Bill
Marijuana can really mess up border and immigration issues for people who partake in consumption or participate in the industry, but that would change if a new bill being introduced in Congress this week is enacted.
Under current U.S. laws, people who admit to past cannabis use or who work for or invest in marijuana businesses can be barred from visiting the country under certain circumstances. And marijuana consumption, even if it is legal under state law, can lead to an immigrant being deported.
The new legislation, the Maintaining Appropriate Protections For Legal Entry Act, would provide exceptions for conduct that “was lawful in the State, Indian Tribe, or foreign country in which the conduct occurred” or that was “subsequently made lawful under the law or regulation of such jurisdiction,” according to a draft obtained by Marijuana Moment.
The bill, known as the MAPLE Act for short—surely a nod to the leaf on Canada’s flag—is being filed on Wednesday by Rep. Earl Blumenauer (D-OR).
U.S. border policies on entry by marijuana industry participants were slightly loosened just ahead of the launch of Canada’s legal marijuana market in October to clarify that people working for cannabis businesses are generally admissible to the U.S., with the caveat that “if a traveler is found to be coming to the U.S. for reason related to the marijuana industry, they may be deemed inadmissible.”
And that’s a key exception. Several Canadians traveling to a cannabis industry conference in Las Vegas last month were detained for hours, with one investor being given a lifetime ban from visiting the U.S.
While there is almost certainly not enough time for Blumenauer’s proposal to be considered and voted on by the end of the year, its language could easily be adopted into new legislation after the 116th Congress is seated in January.
In October, the congressman laid out a plan for a step-by-step approach to federally legalizing marijuana in 2019 in a memo to fellow House Democrats.
Marijuana Moment supporters on Patreon can read the full text of the new MAPLE Act below:
Chicago Mayor Wants Legal Marijuana Revenue To Fund Pensions
Tax revenue from legal marijuana sales should be earmarked to fund pension programs, the mayor of Chicago said on Wednesday.
“Illinois legislators will be taking a serious look next year at legalizing recreational marijuana,” Mayor Rahm Emanuel (D) said in a speech to the City Council. “Should they follow that course, a portion of that revenue could go toward strengthening our pension funds and securing the retirement of the workers who depend on them.”
(Marijuana Moment’s editor provides some content to Forbes via a temporary exclusive publishing license arrangement.)
Photo courtesy of Daniel X. O’Neil.